Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Applied Molecular Transport (NASDAQ:AMTI – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
This is a summary of current recommendations and price targets for Abliva AB (publ) and Applied Molecular Transport, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Abliva AB (publ)||0||0||0||0||N/A|
|Applied Molecular Transport||0||0||2||0||3.00|
Insider & Institutional Ownership
71.3% of Applied Molecular Transport shares are held by institutional investors. 25.4% of Applied Molecular Transport shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Abliva AB (publ) and Applied Molecular Transport’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abliva AB (publ)||$20,000.00||674.18||-$6.54 million||N/A||N/A|
|Applied Molecular Transport||N/A||N/A||-$100.29 million||($3.18)||-1.28|
Abliva AB (publ) has higher revenue and earnings than Applied Molecular Transport.
This table compares Abliva AB (publ) and Applied Molecular Transport’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Abliva AB (publ)||N/A||-81.15%||-71.29%|
|Applied Molecular Transport||N/A||-71.26%||-59.20%|
Applied Molecular Transport beats Abliva AB (publ) on 6 of the 8 factors compared between the two stocks.
Abliva AB (publ) Company Profile (Get Rating)
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Applied Molecular Transport Company Profile (Get Rating)
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.